Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ORCIPRENALINE 2 MG

ORCIPRENALINE SULFATE : 2 MG · DIN 02236565 · APOTEX INC

Health Canada status: APPROVED

What is ORCIPRENALINE?

ORCIPRENALINE 2 MG contains ORCIPRENALINE SULFATE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02236565, held by APOTEX INC, supplied as SYRUP for ORAL administration. Health Canada currently lists it as approved, status dated 17-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ORCIPRENALINE used for?

Bronchial asthma, chronic bronchitis, pulmonary emphysema. May be useful for bronchospasm in sarcoidosis, silicosis, carcinoma of the lung and tuberculosis. Not for acute bronchospasm.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02236565
Brand nameORCIPRENALINE
Generic / active ingredientORCIPRENALINE SULFATE : 2 MG
ManufacturerAPOTEX INC
Strength2 MG
Dosage formSYRUP
Route of administrationORAL
SchedulePrescription
ATC codeR03CB03 ORCIPRENALINE
AHFS class12:12.08.12
BiosimilarNo
Health Canada statusAPPROVED
Status date17-Sep-2021

How is it administered?

Adults: 20 mg (10 mL) 3-4 times daily. Adolescents (12-18): 20 mg (10 mL) 3 times daily. Children (4-12): 10 mg (5 mL) 3 times daily. Max daily dose: 80 mg. Administer orally.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at room temperature (15 - 30°C). Protect from exposure to light.

How is it supplied?

Amber-coloured bottles containing 250 mL of clear syrup.

Contraindications

Hypersensitivity to drug/ingredients; hypertrophic obstructive cardiomyopathy; cardiac arrhythmias with tachycardia; use with beta-blockers; tocolytic use in premature labour/threatened abortion.

Warnings and precautions

Not for acute/deteriorating asthma. Use with care in patients with hypertension, coronary artery disease, CHF, diabetes, glaucoma, or hyperthyroidism. Risk of serious hypokalemia and cardiac effects.

What can be used instead?

Other Canadian products sharing ATC code R03CB03 ORCIPRENALINE. 0 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ALUPENT SYR 10MG/5.0ML10 MG / 5 MLSYRUPBOEHRINGER INGELHEIM (CANADA) LTD LTEECANCELLED POST MARKETDIN 00249920
ALUPENT TAB 20MG20 MGTABLETBOEHRINGER INGELHEIM (CANADA) LTD LTEECANCELLED POST MARKETDIN 00003891
ORCIPREN10 MG / 5 MLSYRUPTECHNILAB PHARMA INC.CANCELLED POST MARKETDIN 02229862
ORCIPRENALINE2 MGSYRUPAA PHARMA INCDORMANTDIN 02236783
RATIO-ORCIPRENALINE SYRUP 2MG/ML2 MGSYRUPRATIOPHARM INC DIVISION OF TEVA CANADA LIMITEDCANCELLED POST MARKETDIN 02152568
TANTA ORCIPRENALINE SYRUP - SYR 2MG/ML2 MGSYRUPTANTA PHARMACEUTICALS INCCANCELLED POST MARKETDIN 02192675

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ORCIPRENALINE

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for ORCIPRENALINE

Health Canada Drug Product Database (DPD), DIN 02236565. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.